adamantanediol | 28996-06-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: adamantanediol
• 英文别名: tricyclo[3.3.1.1^3,7]decane-1,2-diol；1,2-dihydroxyadamantane；adamantane-1,2-diol；1,2-adamantanediol；adamantandiol；adamantane diol
• CAS: 28996-06-7
• 化学式: C₁₀H₁₆O₂
• 分子量: 168.236
• InChiKey: RVIZJROSQMQZCG-UHFFFAOYSA-N

物化性质

• 熔点：
  327-330 °C
• 沸点：
  314.5±10.0 °C(Predicted)
• 密度：
  1.312±0.06 g/cm3(Predicted)
• 保留指数：
  1592;1597;1604;1592;1597

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  adamantanediol 生成 1-羟基-2-金刚烷酮
  参考文献：
  名称：

  Phosphates of bridgehead alcohols as putative inositol monophosphatase inhibitors: molecular design and synthetic approach

  摘要：

  To enhance the lipophilicity of D-3,5,6-trideoxyinositol monophosphate, the IMPase inhibitor, its bridgehead analogues were suggested on the basis of molecular modeling. Adamantane-1,2- and 1,4-diols were converted into their 1-phosphates via the step of benzylic protection of the secondary hydroxy groups; the Baeyer-Villiger oxidation of 1-hydroxyadamantan-2-one occurred to initially cleave C(1)-C(2) bond.

  DOI：

  10.1016/j.mencom.2011.09.003
• 作为产物：
  描述：

  Adamantane-1-carboxylic acid 1-hydroxy-adamantan-2-yl ester 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以81%的产率得到adamantanediol
  参考文献：
  名称：

  Ring-Expansion of Bridgehead Aldehydes with 1-Adamantanecarbonyl Cation or Benzoyl Trifluoromethanesulfonate: A New Route to Bicyclic and Tricyclic 1,2-Diols

  摘要：

  在三氟甲磺酸存在下，桥头醛与由 1-金刚烷阳离子和一氧化碳生成的 1-金刚烷羰基阳离子或与三氟甲磺酸苯甲酰酯发生酰化反应，会使醛环扩张一个碳原子。将反应混合物加水处理后，可得到在邻接碳上含有酰氧基的桥头醇，皂化后可得到邻接二醇，总产率很高。例如，双环[2.2.1]庚烷-1-甲醛可生成双环[2.2.2]辛烷-1,2-二醇，而其他方法很难获得这种物质。

  DOI：

  10.1055/s-1987-28022

文献信息

• SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187535A1

  公开（公告）日：2014-07-03

  The disclosure relates to Substituted Benzimidazole-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable salts or solvates thereof, e.g., a pharmaceutically acceptable salt or solvate, wherein R 1 , R 2 , R 3 , Q a , W, U, A, B, Z, a, and the dashed lines are as defined herein, compositions comprising an effective amount of a Substituted Benzimidazole-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Benzimidazole-Type Piperidine Compound.

  该披露涉及式(I)的取代苯并咪唑基哌啶化合物及其药学上可接受的盐或溶剂，例如药学上可接受的盐或溶剂，其中R1、R2、R3、Qa、W、U、A、B、Z、a和虚线如本文所定义，包括有效量的取代苯并咪唑基哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要的动物施用有效量的取代苯并咪唑基哌啶化合物。
• Method of separating imide compound
  申请人：——

  公开号：US20020169331A1

  公开（公告）日：2002-11-14

  A reaction product and an imide compound can be separated from a reaction mixture obtained by reacting a substrate in the presence of the imide compound having an imide unit represented by the following formula (1): 1 wherein X represents an oxygen atom, a hydroxyl group or an acyloxy group by (A1) a solvent-crystallization step for crystallizing the imide compound with at least one solvent selected from the group consisting of a hydrocarbon, a chain ether and water, (A2) a cooling-crystallization step for crystallizing the reaction product by cooling, or (B) an extraction step for distributing the reaction product into a phase of a water-insoluble solvent and the imide compound into a phase of an aqueous solvent, respectively by using the aqueous solvent containing at least water and the water-insoluble solvent separable from the aqueous solvent. Further, the imide compound and the metal catalyst can be separated from a mixture containing the imide compound and the metal catalyst by (C) a solvent-crystallization step for crystallizing the imide compound by using a solvent for crystallization, (D) an absorption step for absorbing the metal catalyst by an absorption treatment, or (E) an extraction step for distributing the imide compound into a phase of a water-insoluble solvent and the metal catalyst into a phase of an aqueous solvent, respectively by using the aqueous solvent containing at least water and the water-insoluble solvent separable from the aqueous solvent.

  一种反应产物和一种亚酰亚胺化合物可以从通过在亚酰亚胺化合物存在的情况下将底物反应得到的反应混合物中分离出来，该亚酰亚胺化合物具有以下式（1）所表示的亚酰亚胺单元： 1 其中X代表氧原子、羟基或酰氧基 通过（A1）用羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和
• [EN] AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PIPÉRIDINE DE TYPE QUINOXALINE SUBSTITUÉE PAR UNE AZÉTIDINE ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2013080036A1

  公开（公告）日：2013-06-06

  The disclosure relates to Azetidine-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the R1, R2, R3, Q, Y1, Z, A, B, a, and b are as defined herein, compositions comprising an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound.

  该披露涉及公式(I)的氮杂环丙烷取代喹喔啉型哌啶化合物及其药用可接受的衍生物，其中R1、R2、R3、Q、Y1、Z、A、B、a和b如本文所定义，包含有效量氮杂环丙烷取代喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病（如疼痛）的方法，包括向需要的动物施用有效量氮杂环丙烷取代喹喔啉型哌啶化合物。
• OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187544A1

  公开（公告）日：2014-07-03

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及氧肟取代的喹喔啉型哌啶化合物，例如公式（I）中的化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量氧肟取代的喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要治疗的动物施用有效量的氧肟取代的喹喔啉型哌啶化合物。
• Regioselective oxidation of adsorbed alkyl hydrogen succinates by ozone in Freon 11
  作者：Athelstan L. J. Beckwith、Thach Duong

  DOI：10.1039/c39790000690

  日期：——

  The hydrogen succinates of 6-methylheptan-2-ol (1), 3,7-dimethyloctanol (3), adamantan-2-ol (6), cyclododecanol, undecanol, and the isomeric decalols, (8) and (10), when adsorbed on silica-gel, undergo regioselective oxidation at positions remote from the binding site when treated with ozone in Freon 11.

  6-甲基庚-2-醇（1），3,7-二甲基辛醇（3），金刚烷-2-醇（6），环十二烷醇，十一烷醇和异构十氢萘酚的琥珀酸氢盐（8）和（10），当吸附在硅胶上时，在氟利昂11中用臭氧处理时，在远离结合位点的位置进行区域选择性氧化。